ImmuCell (NASDAQ:ICCC) Stock Price Passes Above 200 Day Moving Average – Here’s What Happened

Shares of ImmuCell Corporation (NASDAQ:ICCC) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $6.95 and traded as high as $9.80. ImmuCell shares last traded at $9.77, with a volume of 17,969 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered ImmuCell from a “hold (c-)” rating to a “sell (d-)” rating in a report on Monday, April 6th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

ImmuCell Stock Performance

The business has a fifty day moving average of $8.47 and a 200-day moving average of $6.95. The company has a current ratio of 4.82, a quick ratio of 2.60 and a debt-to-equity ratio of 0.24. The company has a market cap of $88.42 million, a PE ratio of -162.81 and a beta of 0.55.

ImmuCell (NASDAQ:ICCC) last posted its quarterly earnings data on Thursday, May 14th. The biotechnology company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.16. The business had revenue of $10.36 million for the quarter, compared to analysts’ expectations of $5.40 million. ImmuCell had a negative return on equity of 1.88% and a negative net margin of 1.82%.

Institutional Trading of ImmuCell

Hedge funds have recently made changes to their positions in the stock. Militia Capital Management LLC bought a new stake in shares of ImmuCell in the 1st quarter worth approximately $114,000. Steadtrust LLC bought a new stake in shares of ImmuCell in the 3rd quarter worth approximately $198,000. Mesirow Financial Investment Management Inc. raised its holdings in ImmuCell by 199.6% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock worth $224,000 after acquiring an additional 24,303 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in ImmuCell by 3.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company’s stock worth $355,000 after acquiring an additional 1,749 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in ImmuCell by 4.2% during the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock valued at $500,000 after buying an additional 2,907 shares during the last quarter. 13.47% of the stock is owned by institutional investors.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.